Shiri Shulman1, Gauti Jóhannesson2, Einar Stefánsson3, Anat Loewenstein1, Amir Rosenblatt1, Zohar Habot-Wilner1. 1. Division of Ophthalmology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 2. Department of Clinical Science, Ophthalmology, Umeå University, Umeå, Sweden. 3. Department of Ophthalmology, National Hospital Reykjavik, University of Iceland, Reykjavik, Iceland.
Abstract
PURPOSE: To evaluate the safety and efficacy of 1.5% dexamethasone nanoparticle (DexNP) drops in eyes with non-infectious uveitic macular oedema and vitritis. METHODS: In a prospective pilot study, DexNP drops were administered four times a day for 4 weeks followed by drops tapering over a period of another 4 weeks. Follow-up time was 12 weeks. RESULTS: Five eyes with macular oedema and three eyes with vitritis were included in the study. Best corrected visual acuity (BCVA) significantly improved from a median of 0.2 logMAR to a median of 0.15 logMAR at 4 weeks' time (p < 0.05). Median BCVA was 0.175 logMAR and 0.2 logMAR, at week 8 and 12, respectively (p > 0.05). Macular oedema significantly improved at all time-points as compared to baseline (p < 0.05) and resolved in all eyes during follow-up. One eye had macular oedema relapse at week 12. Vitritis improved in all eyes and resolved completely in two eyes. One eye had intraocular pressure (IOP) elevation which was well controlled with topical antihypertensive treatment, and one eye had cataract progression. CONCLUSION: This short pilot study demonstrates favourable effect of 1.5% DexNP eye drops on eyes with non-infectious uveitic macular oedema and vitritis. Further comparative long-term studies are warranted to assess this effect.
PURPOSE: To evaluate the safety and efficacy of 1.5% dexamethasone nanoparticle (DexNP) drops in eyes with non-infectious uveitic macular oedema and vitritis. METHODS: In a prospective pilot study, DexNP drops were administered four times a day for 4 weeks followed by drops tapering over a period of another 4 weeks. Follow-up time was 12 weeks. RESULTS: Five eyes with macular oedema and three eyes with vitritis were included in the study. Best corrected visual acuity (BCVA) significantly improved from a median of 0.2 logMAR to a median of 0.15 logMAR at 4 weeks' time (p < 0.05). Median BCVA was 0.175 logMAR and 0.2 logMAR, at week 8 and 12, respectively (p > 0.05). Macular oedema significantly improved at all time-points as compared to baseline (p < 0.05) and resolved in all eyes during follow-up. One eye had macular oedema relapse at week 12. Vitritis improved in all eyes and resolved completely in two eyes. One eye had intraocular pressure (IOP) elevation which was well controlled with topical antihypertensive treatment, and one eye had cataract progression. CONCLUSION: This short pilot study demonstrates favourable effect of 1.5% DexNP eye drops on eyes with non-infectious uveitic macular oedema and vitritis. Further comparative long-term studies are warranted to assess this effect.
Authors: I Bravo-Osuna; V Andrés-Guerrero; P Pastoriza Abal; I T Molina-Martínez; R Herrero-Vanrell Journal: Drug Deliv Transl Res Date: 2016-12 Impact factor: 4.617
Authors: Kongnara Papangkorn; Eri Prendergast; John W Higuchi; Balbir Brar; William I Higuchi Journal: J Ocul Pharmacol Ther Date: 2017-10-12 Impact factor: 2.671
Authors: Sahar Awwad; Abeer H A Mohamed Ahmed; Garima Sharma; Jacob S Heng; Peng T Khaw; Steve Brocchini; Alastair Lockwood Journal: Br J Pharmacol Date: 2017-10-10 Impact factor: 8.739
Authors: Abeer H A Mohamed-Ahmed; Alastair Lockwood; He Li; Maryse Bailly; Peng T Khaw; Steve Brocchini Journal: Invest Ophthalmol Vis Sci Date: 2017-07-01 Impact factor: 4.799